Drug intelligence / Profile preview

oxyfedrine

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular
01

Overview

Oxyfedrine is a small molecule sympathomimetic agent and coronary vasodilator used primarily in the treatment of coronary heart disease, angina pectoris, and acute myocardial infarction. It acts as a partial agonist at β-adrenergic receptors (both β1 and β2), with selectivity over α-adrenergic receptors but can interact with α-receptors at high concentrations. Oxyfedrine improves myocardial metabolism—enabling the heart to better withstand hypoxia—and exerts positive chronotropic and inotropic effects without precipitating angina pectoris. Unlike other vasodilators that may cause the coronary steal phenomenon, oxyfedrine does not worsen angina due to its unique pharmacological profile. Its major active metabolite is norephedrine, which also contributes to its indirectly acting sympathomimetic effects. The drug is chemically unrelated to other antianginal agents[1][4][5][7].

Brand names
IldamenMyofedrin
Other names
oxyfedrine hydrochlorideDL-oxyfedrine
02

Targets

ADRA1A (α1A)ADRB2 (β2)ADRB1 (β1)

Beyond the preview

Go deeper on oxyfedrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on oxyfedrine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call